Condition
Remestemcel-L
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Remestemcell
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
100.0%
1 terminated out of 1 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Terminated1
Clinical Trials (1)
Research Network
Common Treatments
- Remestemcell1
Active Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)1
- Icahn School of Medicine at Mount Sinai1
- Mesoblast, Inc.1
Top Investigators
Baylor Research Institute
Icahn School of Medicine at Mount Sinai
Duke University
Related Conditions
- Acute Respiratory Distress Syndrome1
- Covid1
- Mesenchymal Stromal Cells1